arrow
M

Meg Jardine

University of Sydney
H指数:71
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: insights from the CREDENCE trial

卡格列净在CKD患者中不同联合用药负担下的疗效和安全性具有一致性:来自CREDENCE试验的见解

2026-09-040
OAAI
Variability in eGFR and the Risk of Adverse Kidney Outcomes and All-Cause Mortality A Retrospective Observational Study Based on National General Practice Dataset

eGFR的变异性与不良肾脏结局和全因死亡风险:一项基于全国基层医疗数据库的回顾性观察研究

2026-02-010
PRE
Patterns of follow-up testing of abnormal eGFR and UACR for the detection of chronic kidney disease in Australian primary care: analysis of a national general practice dataset

澳大利亚初级保健中异常eGFR和UACR随访检测模式的慢性肾病筛查:一项全国综合诊所数据集分析

2025-10-010
OAAI
Changing paradigms of studies in kidney diseases

肾脏疾病研究范式的转变

2025-09-290
OAAI
Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset

2型糖尿病伴与不伴慢性肾脏病患者SGLT2抑制剂和GLP1受体激动剂处方的应用现状:一项基于澳大利亚初级保健数据集的分析

2025-07-160
OAAI
Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial

卡格列净在老年人中的心血管,肾脏和安全性结果: 来自CANVAS计划和cre登斯试验的联合分析

2025-01-090
PRE
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial (May, 10.1038/s41591-024-03043-1, 2024)
2024-07-030
OAAI
Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial

坎格列净对整个肾功能谱的总心力衰竭事件的影响: 来自CANVAS计划和cre登斯试验的参与者水平汇总分析

2024-06-261
PRE